SU971337A1 - Method of treating patients ill with alcoholism - Google Patents
Method of treating patients ill with alcoholism Download PDFInfo
- Publication number
- SU971337A1 SU971337A1 SU803227633A SU3227633A SU971337A1 SU 971337 A1 SU971337 A1 SU 971337A1 SU 803227633 A SU803227633 A SU 803227633A SU 3227633 A SU3227633 A SU 3227633A SU 971337 A1 SU971337 A1 SU 971337A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- days
- patients
- people
- day
- leukocytes
- Prior art date
Links
- 208000007848 Alcoholism Diseases 0.000 title claims description 13
- 201000007930 alcohol dependence Diseases 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 8
- 206010019133 Hangover Diseases 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229960000903 pantethine Drugs 0.000 claims description 4
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- URCYCZPVXXIFSR-UHFFFAOYSA-M 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;bromide Chemical compound [Br-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N URCYCZPVXXIFSR-UHFFFAOYSA-M 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 20
- 210000000265 leukocyte Anatomy 0.000 claims 11
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 10
- 229940055726 pantothenic acid Drugs 0.000 claims 10
- 235000019161 pantothenic acid Nutrition 0.000 claims 10
- 239000011713 pantothenic acid Substances 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 210000002700 urine Anatomy 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- LCTONWCANYUPML-UHFFFAOYSA-N PYRUVIC-ACID Natural products CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 238000001784 detoxification Methods 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 206010044565 Tremor Diseases 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 3
- 230000035622 drinking Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229940107700 pyruvic acid Drugs 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 206010012374 Depressed mood Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 238000005353 urine analysis Methods 0.000 claims 2
- 210000001835 viscera Anatomy 0.000 claims 2
- 235000013522 vodka Nutrition 0.000 claims 2
- -1 1.23 Chemical compound 0.000 claims 1
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 claims 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims 1
- BUCORZSTKDOEKQ-UHFFFAOYSA-N 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine Chemical compound C=12C=C(Cl)C=CC2=NC(=NC)CN(O)C=1C1=CC=CC=C1 BUCORZSTKDOEKQ-UHFFFAOYSA-N 0.000 claims 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010048714 Gastroduodenitis Diseases 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 206010021135 Hypovitaminosis Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 206010028347 Muscle twitching Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 claims 1
- 206010043458 Thirst Diseases 0.000 claims 1
- 102000003929 Transaminases Human genes 0.000 claims 1
- 108090000340 Transaminases Proteins 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 235000013334 alcoholic beverage Nutrition 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 201000011068 alcoholic psychosis Diseases 0.000 claims 1
- 230000002075 anti-alcohol Effects 0.000 claims 1
- 208000024823 antisocial personality disease Diseases 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 238000004159 blood analysis Methods 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 238000009534 blood test Methods 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 201000006368 chronic pyelonephritis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 238000009535 clinical urine test Methods 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000003400 hallucinatory effect Effects 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002906 microbiologic effect Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 229960003196 unithiol Drugs 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 230000036642 wellbeing Effects 0.000 claims 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(5) СПОСОБ ЛЕЧЕНИЯ БОЛЬШХ АЖОГОЛИЗМОМ(5) METHOD OF TREATMENT OF GREATER AHOHOLISM
1one
Изобретение относитс к области медицины, а именно наркологии, и может быть использовано в витаминотерапии больных алкоголизмом. The invention relates to the field of medicine, namely narcology, and can be used in the vitamin therapy of alcoholics.
- Известен способ лечени больных .алкоголизмом путем введени витаминных препаратов , РР С Однако известный способ не обеспеччивает стабильного терапевтического эффекта, введение больших доз одновременно может вызвать осложнени , а срок купировани похмельного синдрома длитс до 3-5 дней.- A known method of treating patients with alcoholism by administering vitamin preparations, PP C However, the known method does not provide a stable therapeutic effect, the administration of large doses at the same time can cause complications, and the period of relief of the hangover syndrome lasts up to 3-5 days.
Целью изобретени вл етс сокращение сроков купировани похмельного синдрома.The aim of the invention is to reduce the time to stop a hangover syndrome.
Цель достигаетс тем, что при осуществлении способа лечени больных алкоголизмом путем введени витаминных препаратов , РР отличительной особенностью вл етс то, что .. дополнительно ввод т препарат панто син (пантетин - Дайичи) в количестве .120-250 мг в сутки в течение 7-10 дней.The goal is achieved by the fact that, when implementing the method of treating patients with alcoholism by administering vitamin preparations, the PP is distinguished by the fact that ... additionally administered the drug pantoin (pantethine - Daiichi) in an amount of 120-250 mg per day for 7- 10 days.
Лечение провод т по схеме:ripenaрат пантосин (пантетин-Дайичи) в дозе 120 мг от 1 до 2 раз Б день 710 дней peros иливнутримышечно; раствор тиамина бромида 6%-ный по 3 мл 1 раз в день внутримышечно 5-6 дней; раствор рибофлавина 1%-ный The treatment is carried out according to the following scheme: ripenarat pantosin (pantetin-Daiichi) at a dose of 120 mg 1 to 2 times B day 710 days peros or intramuscularly; 6% thiamine bromide solution, 3 ml once a day intramuscularly 5-6 days; riboflavin solution 1%
0 по 1 мл внутримышечно 1 раз в день 10 дней; никотинова кислота по 100мг 2 раза в день в порошках - 10 дней.0 1 ml intramuscularly 1 time per day for 10 days; nicotinic acid 100 mg 2 times a day in powders - 10 days.
Данный лекарственный комплекс назначалс больным параллельно с другими This drug complex was administered to patients in parallel with other
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU803227633A SU971337A1 (en) | 1980-11-20 | 1980-11-20 | Method of treating patients ill with alcoholism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU803227633A SU971337A1 (en) | 1980-11-20 | 1980-11-20 | Method of treating patients ill with alcoholism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU971337A1 true SU971337A1 (en) | 1982-11-07 |
Family
ID=20935551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU803227633A SU971337A1 (en) | 1980-11-20 | 1980-11-20 | Method of treating patients ill with alcoholism |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU971337A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005096717A3 (en) * | 2004-04-08 | 2005-12-29 | Eugeni Ilyich Mayevsky | Agent exhibiting hepatoprotective properties |
| US20110280977A1 (en) * | 2010-04-16 | 2011-11-17 | Hyun-Jun Park | Composition for relieving and preventing hangover and beverage comprising composition |
-
1980
- 1980-11-20 SU SU803227633A patent/SU971337A1/en active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005096717A3 (en) * | 2004-04-08 | 2005-12-29 | Eugeni Ilyich Mayevsky | Agent exhibiting hepatoprotective properties |
| US20110280977A1 (en) * | 2010-04-16 | 2011-11-17 | Hyun-Jun Park | Composition for relieving and preventing hangover and beverage comprising composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Isbell et al. | An experimental study of the etiology of “rum fits” and delirium tremens | |
| Stockwell et al. | Alcohol dependence, beliefs and the priming effect | |
| EP2881112B1 (en) | Pharmaceutical composition for promoting nerve injury restoration and application thereof | |
| Klein et al. | Periodic paralysis with cardiac arrhythmia | |
| Victor | The effects of alcohol on the nervous system | |
| Ohira et al. | Work capacity after iron treatment as a function of hemoglobin and iron deficiency | |
| SU971337A1 (en) | Method of treating patients ill with alcoholism | |
| Latham | On nervous or sick-headache: Its varieties and treatment | |
| RU2132203C1 (en) | Method of tobacco dependency treatment and antitobacco combination preparation | |
| McCaul et al. | Conditioned opponent responses: Effects of placebo challenge in alcoholic subjects | |
| Kräuchi et al. | Accelerated post-glucose glycaemia and altered alliesthesia-test in Seasonal Affective Disorder | |
| HARTMAN et al. | Further experience with cortin therapy | |
| Barrera et al. | THE USE OF ANTABUSE (TETRAETHYLTHIURAMIDISULPHIDE) IN CHRONIC ALCOHOLICS | |
| RU2178288C2 (en) | Method for treating nervous system diseases | |
| Hinsie | The treatment of schizophrenia: A survey of the literature | |
| Clayson | Effect of hypoglycemia on T-maze learning in rats | |
| RU2503449C1 (en) | Method for detoxification-infusion therapy of patients used psychotropic cannabis products | |
| SU1734754A1 (en) | Nootropic remedy | |
| CN107115332A (en) | It is a kind of to be used to treat composition of motor neuron disease and application thereof | |
| RU2645612C2 (en) | Method of tobacco dependence treatment | |
| EP0542303B1 (en) | Process for preparing a biologically-active human blood serum | |
| Stone et al. | VITAMIN B AND E THERAPY IN TABES DORSALIS:(Preliminary Report on the Use of Wheat Germ Oil, Vitamin B Complex and Intraspinal Administration of Thiamin Chloride) | |
| FERRISS et al. | Hepatolenticular Degeneration: Follow-Up Report of a Case Treated with Dimercaprol (BAL), Potassium Sulfide, and High-Protein Diet | |
| Victor | The Effects of Alcohol on the Nervous | |
| PREU et al. | Symptomatic psychoses in pernicious anemia |